Compass Pathways to Highlight Treatment-Resistant Depression Research and Launch New HCP Education Campaign at Psych Congress 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on developing new treatment options for mental health conditions, has announced its participation in Psych Congress 2026, scheduled to take place in New Orleans, Louisiana, from September 14 through September 19, 2026. During the congress, the company plans to showcase its ongoing efforts in treatment-resistant depression (TRD), introduce a new healthcare professional (HCP) education campaign, and present health economics and outcomes research (HEOR) data examining the burden of TRD in real-world clinical practice.
Compass Pathways will also feature new and encore presentations from its clinical development program for COMP360 psilocybin, an investigational therapy being studied for people living with treatment-resistant depression. The company’s activities at Psych Congress are designed to support greater awareness of the challenges associated with TRD, provide clinicians with additional information about the condition, and highlight emerging research into potential new approaches to treatment.
A central focus of Compass Pathways’ presence at the congress will be the debut of “Change the Tune in TRD,” a new educational initiative developed specifically for U.S. healthcare professionals. The campaign will explore the neurobiology associated with treatment-resistant depression and discuss approaches to navigating treatment pathways for patients whose depression has not responded adequately to existing therapies.
New “Change the Tune in TRD” Education Campaign
Treatment-resistant depression represents a significant challenge for patients and healthcare professionals because individuals may continue to experience substantial symptoms despite receiving multiple conventional treatments. Determining when depression has become treatment-resistant, understanding the underlying biology, and selecting an appropriate next step in care can all present challenges in clinical practice.
Compass Pathways’ new Change the Tune in TRD campaign is intended to provide educational resources that explore these issues. The initiative will focus on the neurobiology of TRD as well as the practical considerations involved in navigating care pathways.
The campaign will officially debut during a three-panel Innovation Theater session at Psych Congress on September 15. The session is scheduled from 12:15 p.m. to 1:30 p.m. in Room 220-222.
The panel will bring together clinicians and mental health experts with experience across psychotherapy, psychiatry, and interventional psychiatry. The featured panelists are Saundra Jain, MA, PsyD, LPC, psychotherapist and adjunct clinical affiliate at the University of Texas at Austin School of Nursing, as well as a private practitioner in Austin, Texas; Bryan B. Shapiro, MD, MPH, board-certified psychiatrist and assistant clinical professor of psychiatry at UC Irvine Medical Center; and Sandhya Prashad, MD, an interventional psychiatrist and founder and medical director of Sandhya J. Prashad, MD, Houston Ketamine Therapeutics, and Houston TMS Therapeutics.
The diverse clinical perspectives represented on the panel are expected to provide attendees with insight into the challenges associated with recognizing and managing TRD and the different considerations involved in treatment decision-making.
HEOR Research to Examine the Real-World Burden of TRD
Another major component of Compass Pathways’ participation will be the presentation of new HEOR research examining treatment-resistant depression in real-world settings.
Health economics and outcomes research can provide important information beyond clinical trial efficacy and safety results. By examining healthcare resource utilization, costs, treatment patterns, and provider experiences, HEOR studies can help illustrate the broader impact of a disease on patients, healthcare systems, and clinicians.
Compass Pathways will present four new HEOR analyses during Psych Congress 2026.
The first presentation, “Real-World Healthcare Costs and Resource Utilization Across Health States Among Patients with Treatment-Resistant Depression,” will be presented by Yechu Hua as poster #186. The research examines healthcare costs and resource utilization associated with different health states among individuals with TRD, providing insight into the economic burden associated with the condition.
A second presentation, “Characterization of Depression Episodes to Inform Real-World Health States for Major Depressive Disorder and Treatment-Resistant Depression,” will be presented by Vicki Wing as poster #88. This research focuses on characterizing depression episodes and generating information that can be used to better define real-world health states for people with major depressive disorder and treatment-resistant depression.
The third HEOR presentation, “Behavioral Health Provider Perspectives on Management of Individuals with TRD,” will be presented by Caroline Hostetler as poster #95. The analysis is expected to provide insight into how behavioral health providers approach the management of individuals with treatment-resistant depression and the challenges they encounter in clinical practice.
The fourth presentation, “Identifying Treatment-Resistant Depression in the Real-World: Clinical Practice and Barriers to Care,” will be presented by Matthew Sidovar as poster #89. The research addresses the identification of TRD in routine clinical settings and explores potential barriers that can make recognition and management of treatment-resistant depression difficult.
Taken together, these four studies are intended to broaden understanding of TRD beyond controlled clinical trials by examining healthcare costs, resource utilization, disease-state characterization, provider perspectives, and real-world barriers to diagnosis and care.
COMP360 Psilocybin Clinical Development Program
Compass Pathways will also present several encore analyses from its COMP360 psilocybin clinical development program at Psych Congress 2026.
COMP360 is an investigational psilocybin formulation being studied by the company as a potential treatment for treatment-resistant depression. The program includes clinical trials designed to evaluate the efficacy, safety, and durability of treatment effects in individuals with TRD.
One presentation, “Demographic and Clinical Characteristics of Participants Receiving COMP360 Psilocybin Treatment for Treatment-Resistant Depression Across Two Pivotal Phase 3 Trials,” will be presented by Kevin Loh as poster #93. The analysis will provide information on the demographic and clinical characteristics of participants enrolled across two pivotal Phase 3 studies.
Understanding the characteristics of patients participating in clinical trials is important for interpreting study results and evaluating how research populations may relate to individuals encountered in routine clinical practice. Such analyses can also provide context regarding the populations being studied in the development program.
Another encore presentation, “Durability of Efficacy and Safety of COMP360 Psilocybin for Treatment-resistant Depression Across 26 Weeks in a Double-blind, Randomised, Controlled Phase 3 Study,” will be presented by Collin Challis as poster #92.
Durability is an important consideration when evaluating potential treatments for depression. While an initial improvement in symptoms can be clinically meaningful, sustained benefits over an extended period are also relevant to patients and healthcare professionals. The 26-week analysis will therefore provide additional information concerning the persistence of efficacy and safety findings following COMP360 treatment in the Phase 3 study.
The third encore presentation, “Efficacy and Safety of COMP360 Psilocybin for Treatment-resistant Depression (TRD) in Two Phase 3, Double-blind, Randomized, Controlled Studies,” will be presented by Juliana Gassmann as poster #91.
The presentation will highlight findings from two Phase 3 studies evaluating the efficacy and safety of COMP360 in people with treatment-resistant depression. Double-blind, randomized, controlled trials are designed to provide rigorous comparisons between treatment groups and are an important part of the clinical development process for investigational therapies.
Addressing an Unmet Need in Mental Health Care
Compass Pathways’ presence at Psych Congress comes as researchers, clinicians, and healthcare organizations continue to seek new approaches for patients who do not achieve adequate symptom control with existing treatments.
Treatment-resistant depression can be particularly challenging because patients may experience persistent symptoms despite trying multiple antidepressant therapies or other interventions. Continued symptoms can affect daily functioning, quality of life, employment, relationships, and overall health.
For healthcare providers, identifying patients who may have TRD and determining appropriate treatment strategies can also be complicated by differences in treatment history, clinical presentation, comorbidities, access to specialist care, and available therapeutic options.
By combining educational activities with clinical and HEOR research, Compass Pathways aims to address several aspects of the TRD treatment landscape. The company’s Psych Congress program includes educational discussions for clinicians, real-world research examining the burden of the disease, and clinical data from its investigational COMP360 development program.
Broad Engagement at Psych Congress 2026
In addition to its Innovation Theater session and scientific poster presentations, Compass Pathways will maintain two exhibition spaces during the congress.
The company’s Disease State Booth will be located at Booth #901, providing attendees with an opportunity to learn more about treatment-resistant depression and the broader disease landscape.
Compass Pathways will also have a Medical Booth at #937, where healthcare professionals can engage with the company’s medical team and obtain additional information regarding its clinical development activities.
These exhibition spaces will complement the company’s scientific presentations and educational programming throughout the meeting.
Compass Pathways’ participation in Psych Congress 2026 represents a broad effort to increase awareness of treatment-resistant depression while sharing research from its clinical and HEOR programs. The introduction of the Change the Tune in TRD campaign provides a dedicated educational platform for U.S. healthcare professionals to explore the neurobiology of TRD and consider approaches to navigating care pathways.
At the same time, the company’s four HEOR presentations will provide additional perspectives on the real-world impact of TRD, including healthcare costs, resource utilization, disease-state characterization, provider experiences, and barriers to identifying the condition.
The COMP360 encore presentations will add further information from the company’s Phase 3 clinical development program, covering participant characteristics, the durability of efficacy and safety over 26 weeks, and findings from two pivotal Phase 3 studies.
Together, these activities reflect Compass Pathways’ focus on advancing research and education in treatment-resistant depression. As the company continues to develop COMP360 and investigate potential new treatment options, data from clinical trials and real-world research may contribute to a deeper understanding of the needs of patients and healthcare professionals affected by TRD.
With Psych Congress 2026 bringing together mental health professionals and industry stakeholders in New Orleans, Compass Pathways will use the event to engage with the clinical community, present emerging research, and introduce educational initiatives aimed at supporting a more informed understanding of treatment-resistant depression and its management.
About treatment resistant depression (TRD)
Depression, one of the most common mental health disorders, significantly impacts relationships, work performance, overall quality of life, and is associated with an increased risk of suicide. Major depressive disorder (MDD) has been ranked as the third cause of the burden of disease worldwide in 2008 by the World Health Organization (WHO), which has projected that this disease will rank first by 2030.
It is estimated that approximately 4 million patients in the U.S. with MDD live with TRD1. TRD is broadly defined as an inadequate response to two or more appropriate courses of approved medications. TRD has a significantly greater impact on individuals compared to MDD, leading to residual symptoms, poorer quality of life, increased comorbidities, higher mortality, and an increased risk of suicide compared to non-treatment resistant MDD.
About Compass Pathways
We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD).
COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.
Compass is headquartered in London, UK, with a U.S. office in New York.
We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.